Onconic Therapeutics Overview
- Year Founded
-
2020
- Status
-
Public
- Employees
-
32
- Stock Symbol
-
476060
- Share Price
-
$9.42
- (As of Friday Closing)
Onconic Therapeutics General Information
Description
Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.
Contact Information
Website
www.onconic.co.krCorporate Office
- 11 Floor,12 Teheranro-26-gil
- Gangnam
- Seoul, 06236
- South Korea
Corporate Office
- 11 Floor,12 Teheranro-26-gil
- Gangnam
- Seoul, 06236
- South Korea
Onconic Therapeutics Stock Performance
As of 13-Nov-2026, Onconic Therapeutics’s stock price is $9.42. Its current market cap is $428M with 45.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.42 | $9.20 | $6.04 - $20.04 | $428M | 45.4M | 370K | $0.40 |
Onconic Therapeutics Financials Summary
As of 30-Jun-2026, Onconic Therapeutics has a trailing 12-month revenue of $56.6M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 358,744 | 567,200 | 103,318 | |
| Revenue | 56,621 | 37,517 | 10,875 | 16,105 |
| EBITDA | 14,674 | 9,048 | (7,159) | 1,556 |
| Net Income | 16,711 | 11,091 | (5,931) | 1,287 |
| Total Assets | 60,262 | 52,574 | 41,354 | 29,136 |
| Total Debt | 176 | 87 | 209 | 274 |
Onconic Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Onconic Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Onconic Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Onconic Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Onconic Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Onconic Therapeutics FAQs
-
When was Onconic Therapeutics founded?
Onconic Therapeutics was founded in 2020.
-
Where is Onconic Therapeutics headquartered?
Onconic Therapeutics is headquartered in Seoul, South Korea.
-
What is the size of Onconic Therapeutics?
Onconic Therapeutics has 32 total employees.
-
What industry is Onconic Therapeutics in?
Onconic Therapeutics’s primary industry is Drug Discovery.
-
Is Onconic Therapeutics a private or public company?
Onconic Therapeutics is a Public company.
-
What is Onconic Therapeutics’s stock symbol?
The ticker symbol for Onconic Therapeutics is 476060.
-
What is the current stock price of Onconic Therapeutics?
As of 13-Nov-2026 the stock price of Onconic Therapeutics is $9.42.
-
What is the current market cap of Onconic Therapeutics?
The current market capitalization of Onconic Therapeutics is $428M.
-
What is Onconic Therapeutics’s current revenue?
The trailing twelve month revenue for Onconic Therapeutics is $56.6M.
-
What is Onconic Therapeutics’s annual earnings per share (EPS)?
Onconic Therapeutics’s EPS for 12 months was $0.40.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
